mepa8 Get alerts

FDA warns Rohto over falsified sterility records at Vietnam eye drop plant

The FDA also says Rohto's Cooling Eye Drops products are unapproved new drugs and misbranded, after reviewing the company's labeling, website and Instagram account.

Mepa8 headline card: FDA warns Rohto over falsified sterility records at Vietnam eye drop plant

Key takeaways

  • The FDA issued a warning letter to Rohto Pharmaceutical Co., Ltd. on October 14, 2026, and posted it on November 16, 2026.
  • FDA inspectors at the Rohto-Mentholatum (Vietnam) eye drop plant reported "systemic data falsification" in environmental monitoring, personnel monitoring and cleaning records.
  • Plates read during the April 2026 inspection showed microbial growth, including "approximately 25 ISO 5 excursions," after the firm had reported 0 colony-forming units in nearly all prior sampling.
  • The FDA also called several Rohto Cooling Eye Drops products unapproved new drugs and misbranded.
  • For crews: the products named are ROHTO Cooling Eye Drops COOL RELIEF, ALL-IN-ONE, MAX STRENGTH, DIGI EYE, OPTIC GLOW, DRY AID and DUAL LIGHT RELIEF; the letter does not describe a recall or list lots.

The U.S. Food and Drug Administration issued a warning letter to Rohto Pharmaceutical Co., Ltd. on October 14, 2026. The letter says inspectors found falsified sterility-related records at the company's eye drop plant in Vietnam [1]. The agency posted the letter, MARCS-CMS 733215, on November 16, 2026 [1].

The FDA's Center for Drug Evaluation and Research sent the letter by email to the chairman and representative director of the Osaka-based company [1]. It follows an inspection of Rohto-Mentholatum (Vietnam) Co., Ltd. in the Vietnam - Singapore Industrial Park in Ho Chi Minh, carried out from April 6 to 14, 2026 [1]. According to the letter, the plant uses aseptic processing to make over-the-counter topical ophthalmic drugs [1].

The agency wrote that its inspection "revealed systemic data falsification." It said the breaches "critically undermined assurance of sterility for U.S.-distributed drug products" [1]. On those grounds, the FDA considers the firm's drug products adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act [1].

What the records show

The letter describes three kinds of falsified records: environmental monitoring, personnel monitoring and cleaning [1].

  • Surface monitoring: Company procedure called for surface sampling after each batch. According to the letter, the firm admitted it had repeatedly sent the laboratory "unexposed plates" and had not actually done the sampling. Some other sampling was only partly done [1].
  • Personnel monitoring: The FDA says production and engineering staff who worked in the aseptic processing room were never sampled. Unexposed plates went to the lab instead, and the records showed the sampling as completed [1].
  • Air sampling: In one case, active air samples for a batch were taken at the wrong locations but recorded as taken at the required ones [1].
  • Cleaning: Records said ISO 5 surfaces were cleaned on January 23, January 30, March 10 and March 21, 2026. Inspectors found no evidence the cleaning happened. According to the letter, management confirmed the work was not done and that the records were false [1].

The letter compares the firm's own numbers with what inspectors found. In the period under review, the company reported 0 colony-forming units across all environmental and personnel monitoring samples. The only exception was a single deviation after a water leak [1]. Plates read during the inspection, from April 10 to 14, 2026, showed microbial growth in many samples, including "approximately 25 ISO 5 excursions," according to the FDA [1]. The letter also cites the regulations on laboratory records and on equipment cleaning, 21 CFR 211.194(a) and 21 CFR 211.67(a) [1].

A second set of findings came from an August 2026 FDA review of product labeling, the website rohtoeyedrops.com and the company's Instagram account [1]. The agency concluded that these products are unapproved new drugs under section 505(a) and are misbranded under sections 502(a) and 502(ee) [1]:

  • ROHTO Cooling Eye Drops COOL RELIEF
  • ROHTO Cooling Eye Drops ALL-IN-ONE
  • ROHTO Cooling Eye Drops MAX STRENGTH
  • ROHTO Cooling Eye Drops DIGI EYE
  • ROHTO Cooling Eye Drops OPTIC GLOW
  • ROHTO Cooling Eye Drops DRY AID
  • ROHTO Cooling Eye Drops DUAL LIGHT RELIEF

The company responded to the FDA's Form 483 on May 1, 2026, and the agency acknowledged later correspondence [1]. According to the letter, Rohto said in its response that it had stopped making drugs for the U.S. market and had told its U.S. distributor that distribution needed to stop. The firm also admitted that the monitoring and cleaning records were falsified and named several root causes, including a lack of independent oversight [1].

Why it matters for EMS

The products named in the letter are eye drops sold over the counter, so they can appear on a patient's home medication list without a prescription. The FDA's central finding concerns sterility. The agency says the firm had no reliable data showing environmental control in its aseptic operations, or supporting the release of batches to the U.S. market [1]. The letter does not link any patient illness to these products.

What the records do not tell us

The posted letter does not describe a recall. It does not name affected lots, expiration dates or quantities shipped to the United States. It does not report any injuries, infections or adverse event reports tied to these products. The letter does not say whether the microbes found during the inspection were identified, or whether any finished product was tested and found contaminated. The available text of the letter is cut off partway through the FDA's review of the company's response, so the agency's full assessment of that response is not in the packet. The records include no public comment from Rohto.

What to watch

The FDA warned that if the violations are not adequately addressed, it may take regulatory action without further notice [1]. The letter does not set a specific deadline or date for the next step.

Questions readers ask

Why did the FDA send Rohto a warning letter?

According to the October 14, 2026 letter, FDA inspectors found systemic falsification of environmental monitoring, personnel monitoring and cleaning records at Rohto-Mentholatum (Vietnam), a plant that makes over-the-counter eye drops. The FDA also said several ROHTO Cooling Eye Drops products are unapproved new drugs and misbranded.

Which Rohto eye drops are named in the FDA warning letter?

The letter names ROHTO Cooling Eye Drops COOL RELIEF, ALL-IN-ONE, MAX STRENGTH, DIGI EYE, OPTIC GLOW, DRY AID and DUAL LIGHT RELIEF.

Are Rohto Cooling Eye Drops recalled?

The posted warning letter does not describe a recall or list affected lots. It says Rohto told the FDA it had stopped production for the U.S. market and had told its U.S. distributor that distribution needed to stop.

Did the FDA find contamination at the Rohto Vietnam plant?

The FDA says plates read during the April 10 to 14, 2026 inspection showed microbial growth in many samples, including approximately 25 ISO 5 excursions. Before that, the firm had reported 0 colony-forming units in nearly all of its sampling.

Sources

  1. FDA warning letter: Rohto Pharmaceutical Co., Ltd. - 733215 - 10/14/2026 — fda.gov (2026-11-16). fda.gov/inspections-compliance-enforcement-and-criminal-investigations
How this story was made Drafted by Mepa8's AI newsroom from the 1 record listed above and nothing else. Before publication a verification program confirmed that every number and quotation in the story appears in those records, that no passage was copied from them, and that every cited link opens. Editor: Ryan Bolden, EMS professional, who reviews published stories and handles corrections. Medical review pending. How we use AI · Report an error

This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.

Free alerts

Know about the next recall or outbreak the day it is posted.

One email when a story touches EMS equipment, medications or public health. Plus the free 6am briefing if you want it.

Send me